tamoxifen

Matteo Lambertini MD PhD discusses new findings from the ALTTO trial at the 2025 San Antonio Breast Cancer Symposium. The long-term analysis reveals that adjuvant aromatase inhibitors lead to superior outcomes, including improved disease-free survival and time to distant recurrence, compared to tamoxifen or other SERMs.

Scientific Editors: George Canellos (Boston), Pat Price (Manchester), Gianni Bonadonna (Milan), Gordon McVie (Milan) Commenting Expert: Emiel Rutgers, Netherlands Cancer Institute, Amsterdam Angel Rod

Jack Cuzick JACK CUZICK, Wolfson Institute of Preventive Medicine, London New data from the ATAC trial, which is testing anastrozole and tamoxifen in early breast cancer, have demonstrated the continu

Lorie Hughes Rachel Ellsworth Rowan Chlebowski Victor Vogel Local Excision Alone for Selected Patients with Ductal Carcinoma In Situ? REFERENCE: Abstract: 29 LORIE HUGHES, The Hope Center, Cartersvill

Rachel Johnson Terry Mamounas William Gradishar Withhold Trastuzumab in Low-Risk Patients with HER-2 Positive Breast Cancer? REFERENCE: Abstract: 2090 RACHEL JOHNSON, Christie Hospital, Manchester Som

Joan Houghton Elizabeth Barrett-Connor Fran Balkwill Carl Christophe Schimanski Adjuvant Anastrozole for Patients With Breast Cancer: Long-Term Safety Results From the ATAC Study REFERENCE: Lancet Onc

Robert Ozols Lawrence Wickerham Patricia Ganz Jorma Paavonen Noah Kauff Robert Ozols of the Fox Chase Cancer Center in Philadelphia joins Derek Thorne to talk about the top presentations on cancer pre

Julie Gralow Charles Geyer Judith Bliss Robert Coleman Julie Gralow, from the Fred Hutchinson Cancer Research Center in Seattle, joins Derek Thorne to talk about the latest news from the ASCO annual m